Labcorp Holdings Inc. has recently released its 10-Q report, providing insights into the company's financial performance and operations. Labcorp Holdings Inc. is a laboratory services company operating through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers a wide range of tests, including blood chemistry analyses, genetic testing, and drug development solutions, serving various industries such as pharmaceutical, biotechnology, and medical device companies, as well as healthcare providers and patients.
In the 10-Q report, Labcorp Holdings Inc. reported revenues of $3,563.5 million for the three months ended September 30, 2025, marking an 8.6% increase from the corresponding period in 2024. The growth was attributed to organic revenue of 6.2%, acquisitions net of divestitures of 1.7%, and favorable foreign currency translation of 0.7%. For the nine months ended September 30, 2025, the company reported revenues of $10,435.9 million, reflecting a 7.8% increase from the same period in 2024. This growth was driven by organic revenue of 4.6%, acquisitions net of divestitures of 3.0%, and favorable foreign currency translation of 0.3%.
The company defines organic growth as the change in revenue excluding the impact of acquisitions, divestitures, and currency. Labcorp Holdings Inc. completed a Spin-off on June 30, 2023, which is also mentioned in the report. The 10-Q report provides a comprehensive overview of the company's financial condition, results of operations, and forward-looking statements, outlining various factors that could impact its future performance and operations. Following these announcements, the company's shares moved 1.69%, and are now trading at a price of $252.33. If you want to know more, read the company's complete 10-Q report here.
